ReviewNature reviews. Urology2022
Bladder cancer, inflammageing and microbiomes.
Review in Nature reviews. Urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 95 citations in OpenAlex.
- Impact of age on the effectiveness of intravesical Bacillus Calmette‑Guérin and gemcitabine/docetaxel in treatment-naïve high-risk non‑muscle‑invasive bladder cancer.Translational andrology and urology · 2026Article
- Global, regional, and national burdens of bladder cancer in individuals aged 60 years and older from 1990 to 2021: a cross-sectional study.International urology and nephrology · 2026Article
- Multi-omics identification of a programmed cell death-related signature and potential target P4HB for bladder cancer based on a 101-combination machine learning and experimental validation.Clinical and experimental medicine · 2026Article
- Development and validation of a novel senescence-associated gene signature for prediction of survival and endocrine-disrupting chemicals in bladder cancer.Discover oncology · 2026Article
- Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial-Mesenchymal Transition Pathway.Cancer science · 2026Article
- ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation: Insights from whole exome sequencing.Journal of pharmaceutical analysis · 2026Article
- The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer.International journal of molecular sciences · 2025Review
- Synergistic Interactions Between Probiotics and Anticancer Drugs: Mechanisms, Benefits, and Challenges.Probiotics and antimicrobial proteins · 2025Review
- Gut Parabacteroides distasonis-derived Indole-3-Acetic Acid Promotes Phospholipid Remodeling and Enhances Ferroptosis Sensitivity via the AhR-FASN Axis in Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- An interpretable CT-based deep learning model for predicting overall survival in patients with bladder cancer: a multicenter study.NPJ precision oncology · 2025Article
- Circulating metabolic biomarkers mediated causal relationship between gut microbiota and bladder cancer: a two-step mendelian randomization study.Discover oncology · 2025Article
- Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.BMC cancer · 2025Article
- Sarcopenia and lower urinary tract diseases: links, mechanisms, and clinical implications.Frontiers in nutrition · 2025Review
- Epigenetic regulation of bladder cancer in the context of aging.Frontiers in pharmacology · 2025Review
- Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.Frontiers in oncology · 2025Article
- Host-microbe-cancer interactions on-a-chip.Frontiers in bioengineering and biotechnology · 2025Review
- From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis.Frontiers in oncology · 2025Review
- Risk of Bladder Cancer in Patients with Chronic Indwelling Catheters: A Real-World Data Analysis.Journal of Cancer · 2025Article
- Preclinical models of bladder cancer: BBN and beyond.Nature reviews. Urology · 2024Review
- Network Pharmacology Combined with Bioinformatics Analysis to Texplore the Potential Mechanism of Phellodendri Chinensis Cortex Against Bladder Cancer.Cell biochemistry and biophysics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Ageing is correlated with elevated bladder cancer incidence, morbidity and mortality. Advanced age is also associated with elevated markers of chronic inflammation and perturbations in gut and urinary tract microbiota. One reason for the increased incidence and mortality of bladder cancer in the elderly might be that age-associated changes in multiple microbiomes induce systemic metabolic changes that contribute to immune dysregulation with potentially tumorigenic effects. The gut and urinary microbiomes could be dysregulated in bladder cancer, although the effect of these changes is poorly understood. Each of these domains - the immune system, gut microbiome and urinary microbiome - might also influence the response of patients with bladder cancer to treatment. Improved understanding of age-related alterations to the immune system and gut and urinary microbiomes could provide possible insight into the risk of bladder cancer development and progression in the elderly. In patients with bladder cancer, improved understanding of microbiota might also provide potential targets for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.